Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9NPP4

UPID:
NLRC4_HUMAN

ALTERNATIVE NAMES:
CARD, LRR, and NACHT-containing protein; Caspase recruitment domain-containing protein 12; Ice protease-activating factor

ALTERNATIVE UPACC:
Q9NPP4; A8K9F8; B2RBQ3; B3KTF0; D6W580; Q96J81; Q96J82; Q96J83

BACKGROUND:
The NLR family CARD domain-containing protein 4, with alternative names such as Caspase recruitment domain-containing protein 12 and Ice protease-activating factor, is integral to the body's innate immune defense. It indirectly senses specific proteins from intracellular pathogens, assembling an inflammasome complex that promotes an immune response through caspase-1 activation and cytokine production.

THERAPEUTIC SIGNIFICANCE:
Involvement of NLRC4 in diseases like Autoinflammation with infantile enterocolitis and Familial cold autoinflammatory syndrome 4 highlights its significance in human health. These diseases, driven by genetic variants in NLRC4, manifest through severe inflammation and systemic symptoms. Targeting NLRC4's pathway offers a promising avenue for developing treatments for these and potentially other inflammatory conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.